Intas launches first biosimilar to Lucentis

Intas Pharmaceuticals has launched RAZUMAB, its biosimilar to Lucentis (ranibizumab). RAZUMAB will be about 25 percent cheaper than the imported Lucentis


Mr Binish Chudgar, vice chairman, Intas Pharma (Photo Courtesy:

Ranibizumab is a therapeutic antibody fragment designed specifically for treating
degenerative conditions of the eye.

India-based Intas is the first company globally, to develop and launch a biosimilar
version of ranibizumab.

RAZUMAB is manufactured under strict guidelines for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use.

Ranibizumab blocks the production of vascular endothelial cell growth factor A (VEGF-A), a protein which when overexpressed leads to abnormal blood vessel growth in the retina, that can cause leaks and vision loss.

Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly. It is also indicated for Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy in patients with Diabetic Macular Edema and vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV).


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email